A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial.

Citation metadata

Publisher: Frontiers Research Foundation
Document Type: Article
Length: 406 words
Lexile Measure: 1310L

Document controls

Main content

Article Preview :

Author(s): Chia-Che Lee, Chen-Yu Wang, Chih-Chien Hung, Chuan-Ching Huang, Chung-Yi Li, Hsuan-Yu Chen, Yun-Liang Chang, Wo-Jan Tseng, Ting-Ming Wang, Rong-Sen Yang, Tze-Hong Wong, Shau-Huai Fu

<bold>Background:</bold> Though denosumab is an effective treatment for osteoporosis, the rebound effect after discontinuation has drawn investigators' attention. It includes a dramatic loss of gained bone mineral density (BMD) and an increased risk of vertebral fractures. This prospective multi-institutional randomized controlled trial aims to investigate whether zoledronate prevents loss of BMD after discontinuation of denosumab. The trial was registered as Denosumab Sequential Therapy (DST) trial in March 2019 at <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">clinicaltrials.gov</ext-link>, with the identifier...

Source Citation

Source Citation   

Gale Document Number: GALE|A674715664